{"id":"macrolide-therapy","safety":{"commonSideEffects":[{"effect":"Abdominal pain","drugRate":"2.0%","placeboRate":"","totalAtRisk":11167,"totalAffected":228,"trialsReporting":2},{"effect":"Fever","drugRate":"1.8%","placeboRate":"","totalAtRisk":10898,"totalAffected":193,"trialsReporting":1},{"effect":"Constipation","drugRate":"0.8%","placeboRate":"","totalAtRisk":11167,"totalAffected":92,"trialsReporting":2},{"effect":"Pruritis / rash pruritic/ rash/ urticaria","drugRate":"1.4%","placeboRate":"","totalAtRisk":6421,"totalAffected":92,"trialsReporting":1},{"effect":"Diarrhea","drugRate":"0.5%","placeboRate":"","totalAtRisk":17588,"totalAffected":88,"trialsReporting":3},{"effect":"Headache","drugRate":"1.3%","placeboRate":"","totalAtRisk":6421,"totalAffected":84,"trialsReporting":1},{"effect":"Vomiting (any)","drugRate":"0.7%","placeboRate":"","totalAtRisk":10898,"totalAffected":78,"trialsReporting":1},{"effect":"Rash","drugRate":"0.6%","placeboRate":"","totalAtRisk":11167,"totalAffected":72,"trialsReporting":2},{"effect":"Malaria / complicated malaria","drugRate":"0.8%","placeboRate":"","totalAtRisk":6421,"totalAffected":50,"trialsReporting":1},{"effect":"Infections (various, not malaria)","drugRate":"0.4%","placeboRate":"","totalAtRisk":6421,"totalAffected":24,"trialsReporting":1},{"effect":"Vomiting after every feed","drugRate":"0.2%","placeboRate":"","totalAtRisk":10898,"totalAffected":22,"trialsReporting":1},{"effect":"Hypertension","drugRate":"0.3%","placeboRate":"","totalAtRisk":6421,"totalAffected":22,"trialsReporting":1},{"effect":"Cough / Asthma","drugRate":"0.2%","placeboRate":"","totalAtRisk":6421,"totalAffected":15,"trialsReporting":1},{"effect":"Hypotension","drugRate":"0.2%","placeboRate":"","totalAtRisk":6421,"totalAffected":13,"trialsReporting":1},{"effect":"Vomiting","drugRate":"4.1%","placeboRate":"","totalAtRisk":269,"totalAffected":11,"trialsReporting":1},{"effect":"Abdominal pain and/or distension","drugRate":"0.2%","placeboRate":"","totalAtRisk":6421,"totalAffected":11,"trialsReporting":1},{"effect":"Myalgia / musculoskeletal stiffness","drugRate":"0.1%","placeboRate":"","totalAtRisk":6421,"totalAffected":9,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"0.1%","placeboRate":"","totalAtRisk":6421,"totalAffected":7,"trialsReporting":1},{"effect":"Gastritis","drugRate":"0.1%","placeboRate":"","totalAtRisk":6421,"totalAffected":6,"trialsReporting":1},{"effect":"Nausea and/or vomiting","drugRate":"0.1%","placeboRate":"","totalAtRisk":6421,"totalAffected":6,"trialsReporting":1},{"effect":"Dizziness","drugRate":"0.1%","placeboRate":"","totalAtRisk":6421,"totalAffected":6,"trialsReporting":1},{"effect":"Hemorrhoids","drugRate":"1.9%","placeboRate":"","totalAtRisk":269,"totalAffected":5,"trialsReporting":1},{"effect":"Tachycardia or Palpitations","drugRate":"0.1%","placeboRate":"","totalAtRisk":6421,"totalAffected":5,"trialsReporting":1},{"effect":"Fatigue or Asthenia","drugRate":"0.1%","placeboRate":"","totalAtRisk":6421,"totalAffected":5,"trialsReporting":1},{"effect":"Vertigo","drugRate":"0.1%","placeboRate":"","totalAtRisk":6421,"totalAffected":4,"trialsReporting":1},{"effect":"Back or neck pain","drugRate":"0.1%","placeboRate":"","totalAtRisk":6421,"totalAffected":4,"trialsReporting":1},{"effect":"Projectile vomiting","drugRate":"0.0%","placeboRate":"","totalAtRisk":10898,"totalAffected":3,"trialsReporting":1},{"effect":"Sciatica, parasthesia, blurred vision","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":3,"trialsReporting":1},{"effect":"Menstrual bleeding - heavy, inter, menometorrhagia","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":3,"trialsReporting":1},{"effect":"Anemia","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":2,"trialsReporting":1},{"effect":"Lacrimation increased","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":2,"trialsReporting":1},{"effect":"Influenza-like illness, chills or pyrexia","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":2,"trialsReporting":1},{"effect":"Appetite - disorder / decreased","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":2,"trialsReporting":1},{"effect":"Eye pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":1,"trialsReporting":1},{"effect":"Chest pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":1,"trialsReporting":1},{"effect":"Injuries","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":1,"trialsReporting":1},{"effect":"Groin pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":1,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":1,"trialsReporting":1},{"effect":"Nasopharyngitis / oropharangeal pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":1,"trialsReporting":1},{"effect":"Ear pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":0,"trialsReporting":1},{"effect":"Conjunctival/ocular hyperemia or conjunctivitis","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":0,"trialsReporting":1},{"effect":"Eye pruritis","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":0,"trialsReporting":1},{"effect":"Constipation / Hemorrhoids","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":0,"trialsReporting":1},{"effect":"Lip swelling","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":0,"trialsReporting":1},{"effect":"Toothache","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":0,"trialsReporting":1},{"effect":"Pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":0,"trialsReporting":1},{"effect":"Peripheral swelling / swelling","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":0,"trialsReporting":1},{"effect":"Joint swelling / limb discomfort","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":0,"trialsReporting":1},{"effect":"Insomnia","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":0,"trialsReporting":1},{"effect":"Pelvic pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":6421,"totalAffected":0,"trialsReporting":1}]},"_chembl":{"chemblId":"CHEMBL411735","moleculeType":"Small molecule","molecularWeight":"1021.34"},"_dailymed":null,"_scrapedAt":"2026-03-28T01:58:58.927Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T11:12:46.825517+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT04275999","phase":"PHASE2","title":"Rosacea and Ivermectin","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-04-16","conditions":"Rosacea","enrollment":30},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT05773274","phase":"PHASE2","title":"Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-12","conditions":"Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1","enrollment":100},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT07113743","phase":"PHASE1, PHASE2","title":"Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-10","conditions":"Chronic Granulomatous Disease (CGD)","enrollment":10},{"nctId":"NCT02567435","phase":"PHASE3","title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-01","conditions":"Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma","enrollment":325},{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma","enrollment":236},{"nctId":"NCT05896839","phase":"PHASE1, PHASE2","title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-24","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":16},{"nctId":"NCT06876142","phase":"PHASE1, PHASE2","title":"Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM)","enrollment":54},{"nctId":"NCT04235816","phase":"PHASE3","title":"Improving Care Through Azithromycin Research for Infants in Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Barcelona Institute for Global Health","startDate":"2021-03-15","conditions":"Child Mortality","enrollment":20560},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT06959771","phase":"PHASE1, PHASE2","title":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-16","conditions":"CD40L-HyperIgM Syndrome","enrollment":1},{"nctId":"NCT05463133","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":"Chronic Granulomatous Disease","enrollment":50},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT01375829","phase":"PHASE1","title":"Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-27","conditions":"Adult Solid Neoplasm","enrollment":22},{"nctId":"NCT04185402","phase":"PHASE4","title":"Azithromycin Reduction to Reach Elimination of Trachoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-05-29","conditions":"Trachoma","enrollment":3931},{"nctId":"NCT07270549","phase":"PHASE1, PHASE2","title":"Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome","status":"RECRUITING","sponsor":"CTNNB1 Foundation","startDate":"2025-11-01","conditions":"CTNNB1 Neurodevelopmental Syndrome","enrollment":12},{"nctId":"NCT07493538","phase":"PHASE2","title":"MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases","status":"NOT_YET_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2026-08","conditions":"AML, MDS, Acute Leukemia","enrollment":132},{"nctId":"NCT04158258","phase":"","title":"A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-02-21","conditions":"Breast Cancer","enrollment":2907},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":"Chronic Granulomatous Disease","enrollment":4},{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT06943755","phase":"PHASE2, PHASE3","title":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Exelixis","startDate":"2025-07-21","conditions":"Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)","enrollment":440},{"nctId":"NCT06428396","phase":"PHASE2","title":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-27","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT06955169","phase":"PHASE2","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","status":"RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2025-12-24","conditions":"Intracranial Meningioma","enrollment":153},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT05500326","phase":"PHASE2","title":"Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2025-06-24","conditions":"Scabies; Itch, Scabies","enrollment":120},{"nctId":"NCT07487805","phase":"PHASE2","title":"Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-07","conditions":"Solid Tumor, Adult","enrollment":80},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT04141020","phase":"PHASE2","title":"Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms","status":"RECRUITING","sponsor":"University of Miami","startDate":"2021-10-27","conditions":"Cerebral Aneurysm","enrollment":80},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":"Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer","enrollment":700},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT05573126","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":"Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer","enrollment":95},{"nctId":"NCT04287049","phase":"PHASE2","title":"A Study of Standard Drugs for Mycobacterium Avium Complex","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-02-24","conditions":"Mycobacterium Avium Complex","enrollment":10},{"nctId":"NCT05994742","phase":"PHASE3","title":"An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-07-15","conditions":"Severe Acute Malnutrition, HIV, Comorbidities and Coexisting Conditions","enrollment":674},{"nctId":"NCT06751992","phase":"PHASE4","title":"Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-17","conditions":"Kidney Transplant Recipients, Old Age","enrollment":92},{"nctId":"NCT03950609","phase":"PHASE2","title":"Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-30","conditions":"Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1","enrollment":36},{"nctId":"NCT07405164","phase":"PHASE3","title":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Von Hippel-Lindau Disease, Carcinoma, Renal Cell","enrollment":450},{"nctId":"NCT04904588","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2021-09-30","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia","enrollment":300},{"nctId":"NCT01233297","phase":"PHASE2","title":"Antibiotic Treatment of Recurrent Episodes of Asthma in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Copenhagen Studies on Asthma in Childhood","startDate":"2010-11","conditions":"Childhood Asthma With Acute Exacerbation","enrollment":70},{"nctId":"NCT06324357","phase":"PHASE1, PHASE2","title":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-06-03","conditions":"Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":768},{"nctId":"NCT06962800","phase":"PHASE3","title":"A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)","status":"RECRUITING","sponsor":"Biogen","startDate":"2025-05-22","conditions":"Primary Membranous Nephropathy","enrollment":180},{"nctId":"NCT04485559","phase":"PHASE1","title":"Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2020-12-09","conditions":"Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma","enrollment":50},{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":"Healthspan Improvement, Aging, Longevity","enrollment":30},{"nctId":"NCT04802759","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer","enrollment":316},{"nctId":"NCT01804634","phase":"PHASE2","title":"Reduced Intensity Haploidentical BMT for High Risk Solid Tumors","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-27","conditions":"Refractory and/or Relapsed Metastatic Solid Tumors","enrollment":60},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT06289647","phase":"PHASE4","title":"Azithromycin Reduction to Reach Elimination of Trachoma B","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2024-10","conditions":"Trachoma","enrollment":""},{"nctId":"NCT04127578","phase":"PHASE1, PHASE2","title":"Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prevail Therapeutics","startDate":"2020-01-03","conditions":"Parkinson Disease","enrollment":32},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":"Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":240},{"nctId":"NCT05622318","phase":"PHASE2","title":"De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-08-29","conditions":"Graft-versus-host Disease","enrollment":56},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT07300553","phase":"PHASE2","title":"Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-02","conditions":"IBD, Crohn Disease, Ulcerative Colitis (UC)","enrollment":45},{"nctId":"NCT06365437","phase":"PHASE2","title":"A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation","status":"TERMINATED","sponsor":"ITB-Med LLC","startDate":"2021-06-06","conditions":"Kidney Transplantation","enrollment":33},{"nctId":"NCT06752694","phase":"PHASE2","title":"Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-25","conditions":"Aplastic Anemia","enrollment":20},{"nctId":"NCT07204275","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-09-30","conditions":"Primary Membranous Nephropathy","enrollment":176},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT03587272","phase":"PHASE2","title":"Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease","status":"RECRUITING","sponsor":"Robert Nickel","startDate":"2018-04-17","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT02389309","phase":"PHASE1","title":"Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-10-05","conditions":"Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":14},{"nctId":"NCT04965597","phase":"PHASE2","title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-04-19","conditions":"Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia","enrollment":40},{"nctId":"NCT04384692","phase":"PHASE2","title":"Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-18","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":53},{"nctId":"NCT04589845","phase":"PHASE2","title":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-01-18","conditions":"Solid Tumors","enrollment":920},{"nctId":"NCT05918302","phase":"PHASE3","title":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2023-10-27","conditions":"Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms","enrollment":120},{"nctId":"NCT02629120","phase":"PHASE1, PHASE2","title":"High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-17","conditions":"Chronic Granulomatous Disease Transplant","enrollment":45},{"nctId":"NCT06638879","phase":"PHASE1","title":"Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2024-09-17","conditions":"Chronic Graft Versus Host Disease Oral","enrollment":7},{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT05012371","phase":"PHASE2","title":"Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-16","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":90},{"nctId":"NCT05342519","phase":"PHASE2","title":"Daily Topical Rapamycin for Vitiligo","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2022-07-28","conditions":"Vitiligo","enrollment":20},{"nctId":"NCT04861064","phase":"PHASE2","title":"Weekly Sirolimus Therapy","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2022-01-18","conditions":"Venous Malformation, Lymphatic Malformation","enrollment":24},{"nctId":"NCT02333162","phase":"PHASE1","title":"Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2014-12-05","conditions":"Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT06692426","phase":"PHASE1","title":"Trial of Cell Based Therapy for DMD","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2025-03-20","conditions":"Duchenne Muscular Dystrophy","enrollment":8},{"nctId":"NCT04873362","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-04","conditions":"Breast Cancer","enrollment":1188},{"nctId":"NCT04311671","phase":"PHASE3","title":"Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole","status":"COMPLETED","sponsor":"Medicines Development for Global Health","startDate":"2021-05-03","conditions":"Onchocerciasis","enrollment":12979},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT07445282","phase":"PHASE4","title":"This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever","status":"COMPLETED","sponsor":"Sheikh Zayed Medical College","startDate":"2025-05-14","conditions":"Extensively Drug-Resistant Typhoid Fever, Typhoid Fever, Salmonella Typhi Infection","enrollment":90},{"nctId":"NCT04895748","phase":"PHASE1","title":"DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-30","conditions":"Carcinoma, Renal Cell","enrollment":40},{"nctId":"NCT03933904","phase":"PHASE2","title":"Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2019-09-25","conditions":"Castleman Disease, Castleman's Disease, Multicentric","enrollment":7},{"nctId":"NCT07443436","phase":"PHASE2","title":"Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-10-01","conditions":"Interstitial Lung Disease","enrollment":30},{"nctId":"NCT05949190","phase":"NA","title":"Improving Cognition and Gestational Duration With Targeted Nutrition","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-08-18","conditions":"Malnutrition in Pregnancy, Preterm Birth, Child Development","enrollment":1660},{"nctId":"NCT06055608","phase":"PHASE2","title":"Advancing Transplantation Outcomes in Children","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-05-22","conditions":"Kidney Transplant","enrollment":200},{"nctId":"NCT07435584","phase":"PHASE1, PHASE2","title":"Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"Colorectal Cancer","enrollment":38},{"nctId":"NCT07421141","phase":"PHASE2","title":"De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Radiological Centre of the Ministry of Health of Russia","startDate":"2023-09-01","conditions":"Breast Cancer, HER2-positive Breast Cancer, Early Breast Cancer","enrollment":186},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT07436104","phase":"PHASE4","title":"Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.","status":"COMPLETED","sponsor":"MAHAN Trust","startDate":"2004-01-01","conditions":"Hypertension (HTN), Diarrhea, Pneumonia","enrollment":72564},{"nctId":"NCT04469530","phase":"PHASE2","title":"Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-09-16","conditions":"Solid Tumor","enrollment":55},{"nctId":"NCT02184416","phase":"","title":"Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-10-31","conditions":"Metastatic Renal Cell Carcinoma (mRCC)","enrollment":554},{"nctId":"NCT07433426","phase":"PHASE2","title":"The Impact of Shigellosis and Recommended Treatment in Children","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2026-03-15","conditions":"Diarrhea Infectious, Shigella, Growth & Development","enrollment":700},{"nctId":"NCT05593094","phase":"PHASE1, PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":"Advanced Solid Tumors, HER2-positive Breast Cancer","enrollment":210},{"nctId":"NCT03203525","phase":"PHASE1","title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-23","conditions":"Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver","enrollment":38},{"nctId":"NCT05156710","phase":"PHASE2","title":"BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-09","conditions":"Transplant Rejection","enrollment":48},{"nctId":"NCT05081609","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascendis Pharma Oncology Division A/S","startDate":"2022-01-11","conditions":"Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":320},{"nctId":"NCT04620187","phase":"PHASE2","title":"Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-12-24","conditions":"Salivary Gland Cancer, HER2 Gene Mutation","enrollment":55},{"nctId":"NCT05170828","phase":"PHASE1","title":"Cryopreserved MMUD BM With PTCy for Hematologic Malignancies","status":"WITHDRAWN","sponsor":"Ossium Health, Inc.","startDate":"2022-09","conditions":"Acute Leukemia, Myelodysplastic Syndromes, T-lymphoblastic Lymphoma","enrollment":""},{"nctId":"NCT02811861","phase":"PHASE3","title":"Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2016-10-13","conditions":"Renal Cell Carcinoma","enrollment":1069},{"nctId":"NCT07228624","phase":"PHASE2","title":"Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-02-04","conditions":"Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"structuredTrialResults":[{"hr":"0.77","nctId":"NCT02714283","phase":"","pValue":"0.19","ciLower":"0.51","ciUpper":"1.14","endpoint":"Nontuberculous Mycobacterial (NTM) Disease","enrollment":90089}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["azithromycin","erythromycin"],"phase":"phase_2","status":"active","brandName":"macrolide therapy","genericName":"macrolide therapy","companyName":"Oregon Health and Science University","companyId":"oregon-health-and-science-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":14,"withResults":6},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T11:12:46.825517+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}